Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Methodology

Draft revision of the Institute’s certainty assessment framework, version 2

Consultation on the second version of the framework the Institute uses to rate certainty in a body of evidence. The revision retains the four-level GRADE scale and alters the way the two lowest ratings are explained, after the assessment committee recorded…

Document identifier
CEI-CP-001
Series
Public comment period
Version
1.0
Published
04 Aug 2024
Last reviewed
04 Aug 2024
Next review
04 Aug 2025
Identifier
10.71829/cei.cp.1
Certainty
Not rated
Cycle
2024 Q2
Window
02 May 2024 – 27 Jun 2024
Status
Closed
Submissions
15

§1Consultation and window

§1.1Window

Opened
2 May 2024
Closed
27 June 2024
Duration
56 days
Status
Closed — the disposition is published
Document under consultation
Methodology
Submissions received
15

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Does the revised framework distinguish clearly enough between an absence of evidence and a body of conflicting evidence?
  2. Is the revised treatment of imprecision applicable to safety outcomes, where the event of interest may not have occurred in any contributing trial?
  3. Does the framework remain interoperable with published GRADE guidance, such that an Institute rating can be read against an external assessment using the same scale?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The framework was amended before ratification. The rating scale itself was left unchanged, so that Institute ratings remain readable against external assessments, and the distinction between absent and conflicting evidence is now carried in a standing formulation applied wherever a low or very low rating appears.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.